PFE PFIZER INC

NYSE pfizer.com


$ 24.72 $ -0.13 (-0.5 %)    

Monday, 13-Oct-2025 15:59:02 EDT
QQQ $ 602.22 $ 2.34 (0.39 %)
DIA $ 460.75 $ 2.49 (0.54 %)
SPY $ 663.14 $ 2.46 (0.37 %)
TLT $ 90.58 $ 0.29 (0.33 %)
GLD $ 378.13 $ 1.65 (0.44 %)
$ 24.78
$ 24.80
$ 24.71 x 3,769
$ 24.72 x 5,831
$ 24.62 - $ 24.94
$ 20.18 - $ 27.86
64,963,949
na
140.89B
$ 0.51
$ 13.10
TBD
na
na ($ 0.07)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-29-2025 10-Q
2 05-05-2025 03-30-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-04-2024 09-29-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-22-2024 12-31-2023 10-K
8 11-08-2023 10-01-2023 10-Q
9 08-09-2023 07-02-2023 10-Q
10 05-10-2023 04-02-2023 10-Q
11 02-23-2023 12-31-2022 10-K
12 11-09-2022 10-02-2022 10-Q
13 08-10-2022 07-03-2022 10-Q
14 05-11-2022 04-03-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-12-2021 10-03-2021 10-Q
17 08-12-2021 07-04-2021 10-Q
18 05-13-2021 04-04-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-27-2020 10-Q
21 08-06-2020 06-28-2020 10-Q
22 05-07-2020 03-29-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 11-07-2019 09-29-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-09-2018 07-01-2018 10-Q
30 05-10-2018 04-01-2018 10-Q
31 02-22-2018 12-31-2017 10-K
32 11-09-2017 10-01-2017 10-Q
33 08-10-2017 07-02-2017 10-Q
34 05-11-2017 04-02-2017 10-Q
35 02-23-2017 12-31-2016 10-K
36 11-10-2016 10-02-2016 10-Q
37 08-11-2016 07-03-2016 10-Q
38 05-12-2016 04-03-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-05-2015 09-27-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial 

 pfizer-to-present-46-infectious-disease-abstracts-at-idweek-2025-congress-highlighting-advancements-in-prevention-and-treatment

Pfizer Inc. (NYSE:PFE, "Pfizer"))) will present data across its infectious disease portfolio at the upcoming IDWeek 202...

Core News & Articles

https://www.youtube.com/watch?v=XOtOCzut9pM

 trump-plans-astrazeneca-deal-to-cut-drug-prices-for-low-income-americans

Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing mo...

 morgan-stanley-maintains-equal-weight-on-pfizer-lowers-price-target-to-32

Morgan Stanley analyst Terence Flynn maintains Pfizer (NYSE:PFE) with a Equal-Weight and lowers the price target from $33 to...

 trump-administration-engages-pharmacies-goodrx-for-trumprx-launch

Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers.

 amgen-to-offer-cholesterol-drug-at-60-discount-as-trump-administrations-call-to-lower-drug-prices

Amgen launches AmgenNow, offering Repatha at $239 per month, expanding direct access for U.S. patients with no insurer restrict...

 wall-street-hits-record-highs-as-rate-cut-bets-offset-shutdown-this-week-in-markets

S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easi...

 b-of-a-securities-maintains-neutral-on-pfizer-raises-price-target-to-30

B of A Securities analyst Tim Anderson maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $28 to $30.

 these-3-pharma-stocks-are-rallying--and-still-trade-absurdly-cheap

Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.

 trump-pfizer-deal-pushes-health-care-stocks-to-best-rally-in-5-years

Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tari...

 pfizer-shares-are-trading-higher-wednesday-whats-going-on

Pfizer shares are trading higher Wednesday after Trump announced a drug-pricing deal with the company.

 moderna-stock-is-rallying-wednesday-whats-driving-the-action

Moderna stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector.

 health-care-stocks-rally-nike-beats-the-street-whats-moving-markets-wednesday

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps m...

 stock-of-the-day-will-pfizer-head-higher

Pfizer (PFE) shares may have broken out. This means a large amount of supply has come off the market. This is bullish.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION